Nanomedicine Market Research Reportβ€”Global Forecast till 2030

Nanomedicine Market: Information By Product (Nanoparticles [Metal & Metal Oxide Nanoparticles, Liposomes, Polymers & Polymer-Drug Conjugates, Hydrogel Nanoparticles, Dendrimers], Nanoshells, Nanotubes, and Nanodevices), By Modality (Diagnostics and Treatments), By Application (Drug Delivery, Diagnostic Imaging, Vaccines, Regenerative Medicine, Implants, Biomaterials, and Others) By Indication (Cardiovascular Diseases, Infectious Diseases, Orthopedic Diseases, Neurological Diseases, Oncological Diseases, Anti-Inflammatory Diseases, and O...

ID: MRFR/HC/9348-HCR | August 2022 | Region: Global | 120 Pages         

TABLE OF CONTENTS

1. REPORT PROLOGUE

2. MARKET INTRODUCTION

2.1. Definition

2.2. Scope of the Study

2.2.1. Research Objective

2.2.2. Assumptions

2.2.3. Limitations

3. RESEARCH METHODOLOGY

3.1. Overview

3.2. Data Mining

3.3. Secondary Research

3.4. Primary Research

3.4.1. Primary Interviews and Information Gathering Process

3.4.2. Breakdown of Primary Respondents

3.5. Forecasting Techniques

3.6. Market Size Estimation

3.6.1. Bottom-Up Approach

3.6.2. Top-Down Approach

3.7. Data Triangulation

3.8. Validation

4. MARKET DYNAMICS

4.1. Overview

4.2. Drivers

4.3. Restraints

4.4. Opportunities

5. MARKET FACTOR ANALYSIS

5.1. Porter’s Five Forces Analysis

5.1.1. Bargaining Power of Suppliers

5.1.2. Bargaining Power of Buyers

5.1.3. Threat of New Entrants

5.1.4. Threat of Substitutes

5.1.5. Intensity of Rivalry

5.2. Value Chain Analysis

5.3. COVID-19 Impact Analysis

5.3.1. Market Impact Analysis

5.3.2. Impact on Supply Chain

5.3.3. Impact on Demand

5.3.4. Opportunity and Threat Analysis

6. GLOBAL NANOMEDICINE MARKET, BY PRODUCT

6.1. Overview

6.2. Nanoparticles

Market Estimates & Forecast, by Region, 2022–2030

Market Estimates & Forecast, by Country, 2022–2030

6.2.1. Nanoparticles

6.2.2. Liposomes

6.2.3. Polymers & polymer-drug conjugates

6.2.4. Hydrogel nanoparticles

6.2.5. Dendrimers

6.2.6. Inorganic nanoparticles

6.3. Nano-shells

Market Estimates & Forecast, by Region, 2022–2030

Market Estimates & Forecast, by Country, 2022–2030

6.4. Nanotubes

Market Estimates & Forecast, by Region, 2022–2030

Market Estimates & Forecast, by Country, 2022–2030

6.5. Nanodevices

Market Estimates & Forecast, by Region, 2022–2030

Market Estimates & Forecast, by Country, 2022–2030

7. GLOBAL NANOMEDICINE MARKET, BY MODALITY

7.1. Overview

7.2. Diagnostics

Market Estimates & Forecast, by Region, 2022–2030

Market Estimates & Forecast, by Country, 2022–2030

7.3 Treatments

Market Estimates & Forecast, by Region, 2022–2030

Market Estimates & Forecast, by Country, 2022–2030

8. GLOBAL NANOMEDICINE MARKET, BY APPLICATION

8.1. Overview

8.2. Drug Delivery

Market Estimates & Forecast, by Region, 2022–2030

Market Estimates & Forecast, by Country, 2022–2030

8.3. Diagnostic Imaging

Market Estimates & Forecast, by Region, 2022–2030

Market Estimates & Forecast, by Country, 2022–2030

8.4. Vaccines

Market Estimates & Forecast, by Region, 2022–2030

Market Estimates & Forecast, by Country, 2022–2030

8.5. Regenerative Medicine

Market Estimates & Forecast, by Region, 2022–2030

Market Estimates & Forecast, by Country, 2022–2030

8.6. Active Implants

Market Estimates & Forecast, by Region, 2022–2030

Market Estimates & Forecast, by Country, 2022–2030

8.7. Biomaterials

Market Estimates & Forecast, by Region, 2022–2030

Market Estimates & Forecast, by Country, 2022–2030

8.8. Others

Market Estimates & Forecast, by Region, 2022–2030

Market Estimates & Forecast, by Country, 2022–2030

9. GLOBAL NANOMEDICINE MARKET, BY INDICATION

9.1. Overview

9.2. Cardiovascular diseases

Market Estimates & Forecast, by Region, 2022–2030

Market Estimates & Forecast, by Country, 2022–2030

9.3. Infectious Diseases

Market Estimates & Forecast, by Region, 2022–2030

Market Estimates & Forecast, by Country, 2022–2030

9.4. Orthopedic diseases

Market Estimates & Forecast, by Region, 2022–2030

Market Estimates & Forecast, by Country, 2022–2030

9.5. Neurological diseases

Market Estimates & Forecast, by Region, 2022–2030

Market Estimates & Forecast, by Country, 2022–2030

9.6. Oncological diseases

Market Estimates & Forecast, by Region, 2022–2030

Market Estimates & Forecast, by Country, 2022–2030

9.7. Anti-Inflammatory Disease

Market Estimates & Forecast, by Region, 2022–2030

Market Estimates & Forecast, by Country, 2022–2030

9.8. Others

Market Estimates & Forecast, by Region, 2022–2030

Market Estimates & Forecast, by Country, 2022–2030

10. GLOBAL NANOMEDICINE MARKET, BY REGION

10.1. Overview

10.2. North America

10.2.1. US

10.2.2. Canada

10.3. Europe

10.3.1. Germany

10.3.2. France

10.3.3. Italy

10.3.4. Spain

10.3.5. UK

10.3.6. Rest of Europe

10.4. Asia-Pacific

10.4.1. Japan

10.4.2. China

10.4.3. India

10.4.4. Australia

10.4.5. South Korea

10.4.6. Rest of Asia-Pacific

10.5. Rest of the World

10.5.1. Middle East & Africa

10.5.2. Latin America

11. COMPANY LANDSCAPE

11.1. Overview

11.2. Competitive Analysis

11.3. Market Share Analysis

11.4. Major Growth Strategy in the Global Nanomedicine Market

11.5. Competitive Benchmarking

11.6. Leading Players in Terms of Number of Developments in the Global Nanomedicine Market

11.7. Key Developments and Growth Strategies

11.7.1. New Product Launch/Service Deployment

11.7.2. Merger & Acquisitions

11.7.3. Joint Ventures

11.8. Major Players Financial

11.8.1. Sales & Operating Income, 2021

11.8.2. Major Players R&D Expenditure, 2021

12. COMPANY PROFILES

12.1. Pfizer Inc.

12.1.1. Company Overview

12.1.2. Products Offered

12.1.3. Financial Overview

12.1.4. Key Developments

12.1.5. SWOT Analysis

12.1.6. Key Strategies

12.2. Johnson & Johnson Services, Inc.,

12.2.1. Company Overview

12.2.2. Products Offered

12.2.3. Financial Overview

12.2.4. Key Developments

12.2.5. SWOT Analysis

12.2.6. Key Strategies

12.3. General Electric Company

12.3.1. Company Overview

12.3.2. Products Offered

12.3.3. Financial Overview

12.3.4. Key Developments

12.3.5. SWOT Analysis

12.3.6. Key Strategies

12.4. Invitae Corporation

12.4.1. Company Overview

12.4.2. Products Offered

12.4.3. Financial Overview

12.4.4. Key Developments

12.4.5. SWOT Analysis

12.4.6. Key Strategies

12.5. Leadient BioSciences Inc

12.5.1. Company Overview

12.5.2. Products Offered

12.5.3. Financial Overview

12.5.4. Key Developments

12.5.5. SWOT Analysis

12.5.6. Key Strategies

12.6. Merck & Co., Inc.

12.6.1. Company Overview

12.6.2. Products Offered

12.6.3. Financial Overview

12.6.4. Key Developments

12.6.5. SWOT Analysis

12.6.6. Key Strategies

12.7. DiaSorin S.p.A.

12.7.1. Company Overview

12.7.2. Products Offered

12.7.3. Financial Overview

12.7.4. Key Developments

12.7.5. SWOT Analysis

12.7.6. Key Strategies

12.8. Nanosphere Health Sciences, Inc.

12.8.1. Company Overview

12.8.2. Products Offered

12.8.3. Financial Overview

12.8.4. Key Developments

12.8.5. SWOT Analysis

12.8.6. Key Strategies

12.9. Celgene Corporation

12.9.1. Company Overview

12.9.2. Products Offered

12.9.3. Financial Overview

12.9.4. Key Developments

12.9.5. SWOT Analysis

12.9.6. Key Strategies

12.10. Teva Pharmaceutical Industries Ltd.

12.10.1. Company Overview

12.10.2. Products Offered

12.10.3. Financial Overview

12.10.4. Key Developments

12.10.5. SWOT Analysis

12.10.6. Key Strategies

13. APPENDIX

13.1. References

13.2. Related Reports

 

LIST OF TABLES

TABLE 1 GLOBAL NANOMEDICINE MARKET SYNOPSIS, 2022–2030

TABLE 2 GLOBAL NANOMEDICINE MARKET ESTIMATES & FORECAST, 2022–2030 (USD MILLION)

TABLE 3 GLOBAL NANOMEDICINE MARKET, BY PRODUCT, 2022–2030 (USD MILLION)

TABLE 4 GLOBAL NANOMEDICINE MARKET, BY MODALITY, 2022–2030 (USD MILLION)

TABLE 5 GLOBAL NANOMEDICINE MARKET, BY APPLICATION, 2022–2030 (USD MILLION)

TABLE 6 GLOBAL NANOMEDICINE MARKET, BY INDICATION, 2022–2030 (USD MILLION)

TABLE 7 NORTH AMERICA: NANOMEDICINE MARKET, BY PRODUCT, 2022–2030 (USD MILLION)

TABLE 8 NORTH AMERICA: NANOMEDICINE MARKET, BY MODALITY, 2022–2030 (USD MILLION)

TABLE 9 NORTH AMERICA: NANOMEDICINE MARKET, BY APPLICATION, 2022–2030 (USD MILLION)

TABLE 10 NORTH AMERICA: NANOMEDICINE MARKET, BY INDICATION, 2022–2030 (USD MILLION)

TABLE 11 US: NANOMEDICINE MARKET, BY PRODUCT, 2022–2030 (USD MILLION)

TABLE 12 US: NANOMEDICINE MARKET, BY MODALITY, 2022–2030 (USD MILLION)

TABLE 13 US: NANOMEDICINE MARKET, BY APPLICATION, 2022–2030 (USD MILLION)

TABLE 14 US: NANOMEDICINE MARKET, BY INDICATION, 2022–2030 (USD MILLION)

TABLE 15 CANADA: NANOMEDICINE MARKET, BY PRODUCT, 2022–2030 (USD MILLION)

TABLE 16 CANADA: NANOMEDICINE MARKET, BY MODALITY, 2022–2030 (USD MILLION)

TABLE 17 CANADA: NANOMEDICINE MARKET, BY APPLICATION, 2022–2030 (USD MILLION)

TABLE 18 CANADA: NANOMEDICINE MARKET, BY INDICATION, 2022–2030 (USD MILLION)

TABLE 19 EUROPE: NANOMEDICINE MARKET, BY PRODUCT, 2022–2030 (USD MILLION)

TABLE 20 EUROPE: NANOMEDICINE MARKET, BY MODALITY, 2022–2030 (USD MILLION)

TABLE 21 EUROPE: NANOMEDICINE MARKET, BY APPLICATION, 2022–2030 (USD MILLION)

TABLE 22 EUROPE: NANOMEDICINE MARKET, BY INDICATION, 2022–2030 (USD MILLION)

TABLE 23 GERMANY: NANOMEDICINE MARKET, BY PRODUCT, 2022–2030 (USD MILLION)

TABLE 24 GERMANY: NANOMEDICINE MARKET, BY MODALITY, 2022–2030 (USD MILLION)

TABLE 25 GERMANY: NANOMEDICINE MARKET, BY APPLICATION, 2022–2030 (USD MILLION)

TABLE 26 GERMANY: NANOMEDICINE MARKET, BY INDICATION, 2022–2030 (USD MILLION)

TABLE 27 UK: NANOMEDICINE MARKET, BY PRODUCT, 2022–2030 (USD MILLION)

TABLE 28 UK: NANOMEDICINE MARKET, BY MODALITY, 2022–2030 (USD MILLION)

TABLE 29 UK: NANOMEDICINE MARKET, BY APPLICATION, 2022–2030 (USD MILLION)

TABLE 30 UK: NANOMEDICINE MARKET, BY INDICATION, 2022–2030 (USD MILLION)

TABLE 31 FRANCE: NANOMEDICINE MARKET, BY PRODUCT, 2022–2030 (USD MILLION)

TABLE 32 FRANCE: NANOMEDICINE MARKET, BY MODALITY, 2022–2030 (USD MILLION)

TABLE 33 FRANCE: NANOMEDICINE MARKET, BY APPLICATION, 2022–2030 (USD MILLION)

TABLE 34 FRANCE: NANOMEDICINE MARKET BY INDICATION, 2022–2030 (USD MILLION)

TABLE 35 ITALY: NANOMEDICINE MARKET, BY PRODUCT, 2022–2030 (USD MILLION)

TABLE 36 ITALY: NANOMEDICINE MARKET, BY MODALITY, 2022–2030 (USD MILLION)

TABLE 37 ITALY: NANOMEDICINE MARKET, BY APPLICATION, 2022–2030 (USD MILLION)

TABLE 38 ITALY: NANOMEDICINE MARKET, BY INDICATION, 2022–2030 (USD MILLION)

TABLE 39 SPAIN: NANOMEDICINE MARKET, BY PRODUCT, 2022–2030 (USD MILLION)

TABLE 40 SPAIN: NANOMEDICINE MARKET, BY MODALITY, 2022–2030 (USD MILLION)

TABLE 41 SPAIN: NANOMEDICINE MARKET, BY APPLICATION, 2022–2030 (USD MILLION)

TABLE 42 SPAIN: NANOMEDICINE MARKET, BY INDICATION, 2022–2030 (USD MILLION)

TABLE 43 REST OF EUROPE: NANOMEDICINE MARKET, BY PRODUCT, 2022–2030 (USD MILLION)

TABLE 44 REST OF EUROPE: NANOMEDICINE MARKET, BY MODALITY, 2022–2030 (USD MILLION)

TABLE 45 REST OF EUROPE: NANOMEDICINE MARKET, BY APPLICATION, 2022–2030 (USD MILLION)

TABLE 46 REST OF EUROPE: NANOMEDICINE MARKET, BY INDICATION, 2022–2030 (USD MILLION)

TABLE 47 ASIA-PACIFIC: NANOMEDICINE MARKET, BY PRODUCT, 2022–2030 (USD MILLION)

TABLE 48 ASIA-PACIFIC: NANOMEDICINE MARKET, BY MODALITY, 2022–2030 (USD MILLION)

TABLE 49 ASIA-PACIFIC: NANOMEDICINE MARKET, BY APPLICATION, 2022–2030 (USD MILLION)

TABLE 50 ASIA-PACIFIC: NANOMEDICINE MARKET, BY INDICATION, 2022–2030 (USD MILLION)

TABLE 51 INDIA: NANOMEDICINE MARKET, BY PRODUCT, 2022–2030 (USD MILLION)

TABLE 52 INDIA: NANOMEDICINE MARKET, BY MODALITY, 2022–2030 (USD MILLION)

TABLE 53 INDIA: NANOMEDICINE MARKET, BY APPLICATION, 2022–2030 (USD MILLION)

TABLE 54 INDIA: NANOMEDICINE MARKET, BY INDICATION, 2022–2030 (USD MILLION)

TABLE 55 CHINA: NANOMEDICINE MARKET, BY PRODUCT, 2022–2030 (USD MILLION)

TABLE 56 CHINA: NANOMEDICINE MARKET, BY MODALITY, 2022–2030 (USD MILLION)

TABLE 57 CHINA: NANOMEDICINE MARKET, BY APPLICATION, 2022–2030 (USD MILLION)

TABLE 58 CHINA: NANOMEDICINE MARKET, BY INDICATION, 2022–2030 (USD MILLION)

TABLE 59 JAPAN: NANOMEDICINE MARKET, BY PRODUCT, 2022–2030 (USD MILLION)

TABLE 60 JAPAN: NANOMEDICINE MARKET, BY MODALITY, 2022–2030 (USD MILLION)

TABLE 61 JAPAN: NANOMEDICINE MARKET, BY APPLICATION, 2022–2030 (USD MILLION)

TABLE 62 JAPAN: NANOMEDICINE MARKET, BY INDICATION, 2022–2030 (USD MILLION)

TABLE 63 AUSTRALIA: NANOMEDICINE MARKET, BY PRODUCT, 2022–2030 (USD MILLION)

TABLE 64 AUSTRALIA: NANOMEDICINE MARKET, BY MODALITY, 2022–2030 (USD MILLION)

TABLE 65 AUSTRALIA: NANOMEDICINE MARKET, BY APPLICATION, 2022–2030 (USD MILLION)

TABLE 66 AUSTRALIA: NANOMEDICINE MARKET, BY INDICATION, 2022–2030 (USD MILLION)

TABLE 67 SOUTH KOREA: NANOMEDICINE MARKET, BY PRODUCT, 2022–2030 (USD MILLION)

TABLE 68 SOUTH KOREA: NANOMEDICINE MARKET, BY MODALITY, 2022–2030 (USD MILLION)

TABLE 69 SOUTH KOREA: NANOMEDICINE MARKET, BY APPLICATION, 2022–2030 (USD MILLION)

TABLE 70 SOUTH KOREA: NANOMEDICINE MARKET, BY INDICATION, 2022–2030 (USD MILLION)

TABLE 71 REST OF ASIA-PACIFIC: NANOMEDICINE MARKET, BY PRODUCT, 2022–2030 (USD MILLION)

TABLE 72 REST OF ASIA-PACIFIC: NANOMEDICINE MARKET, BY MODALITY, 2022–2030 (USD MILLION)

TABLE 73 REST OF ASIA-PACIFIC: NANOMEDICINE MARKET, BY APPLICATION, 2022–2030 (USD MILLION)

TABLE 74 REST OF ASIA-PACIFIC: NANOMEDICINE MARKET, BY INDICATION, 2022–2030 (USD MILLION)

TABLE 75 REST OF THE WORLD: NANOMEDICINE MARKET, BY PRODUCT, 2022–2030 (USD MILLION)

TABLE 76 REST OF THE WORLD: NANOMEDICINE MARKET, BY MODALITY, 2022–2030 (USD MILLION)

TABLE 77 REST OF THE WORLD: NANOMEDICINE MARKET, BY APPLICATION, 2022–2030 (USD MILLION)

TABLE 78 REST OF THE WORLD: GLOBAL NANOMEDICINE MARKET, BY INDICATION, 2022–2030 (USD MILLION)

TABLE 79 MIDDLE EAST: NANOMEDICINE MARKET, BY PRODUCT, 2022–2030 (USD MILLION)

TABLE 80 MIDDLE EAST: NANOMEDICINE MARKET, BY MODALITY, 2022–2030 (USD MILLION)

TABLE 81 MIDDLE EAST: NANOMEDICINE MARKET, BY APPLICATION, 2022–2030 (USD MILLION)

TABLE 82 MIDDLE EAST: NANOMEDICINE MARKET, BY INDICATION, 2022–2030 (USD MILLION)

TABLE 83 AFRICA: NANOMEDICINE MARKET, BY PRODUCT, 2022–2030 (USD MILLION)

TABLE 84 AFRICA: NANOMEDICINE MARKET, BY MODALITY, 2022–2030 (USD MILLION)

TABLE 85 AFRICA: NANOMEDICINE MARKET, BY APPLICATION, 2022–2030 (USD MILLION)

TABLE 86 AFRICA: NANOMEDICINE MARKET, BY INDICATION, 2022–2030 (USD MILLION)

TABLE 87 LATIN AMERICA: NANOMEDICINE MARKET, BY PRODUCT, 2022–2030 (USD MILLION)

TABLE 88 LATIN AMERICA: NANOMEDICINE MARKET, BY MODALITY, 2022–2030 (USD MILLION)

TABLE 89 LATIN AMERICA: NANOMEDICINE MARKET, BY APPLICATION, 2022–2030 (USD MILLION)

TABLE 90 LATIN AMERICA: NANOMEDICINE MARKET, BY INDICATION, 2022–2030 (USD MILLION)

LIST OF FIGURES

FIGURE 1 RESEARCH PROCESS

FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL NANOMEDICINE MARKET

FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL NANOMEDICINE MARKET

FIGURE 4 GLOBAL NANOMEDICINE MARKET SHARE, BY PRODUCT, 2021 (%)

FIGURE 5 GLOBAL NANOMEDICINE MARKET SHARE, BY MODALITY, 2021 (%)

FIGURE 6 GLOBAL NANOMEDICINE MARKET SHARE, BY APPLICATION, 2021(%)

FIGURE 7 GLOBAL NANOMEDICINE MARKET SHARE, BY INDICATION, 2021 (%)

FIGURE 8 GLOBAL NANOMEDICINE MARKET SHARE, BY REGION, 2021 (%)

FIGURE 9 NORTH AMERICA: NANOMEDICINE MARKET SHARE, BY REGION, 2021 (%)

FIGURE 10 EUROPE: NANOMEDICINE MARKET SHARE, BY REGION, 2021 (%)

FIGURE 11 ASIA-PACIFIC: NANOMEDICINE MARKET SHARE, BY REGION, 2021 (%)

FIGURE 12 REST OF THE WORLD: NANOMEDICINE MARKET SHARE, BY REGION, 2021 (%)

FIGURE 13 GLOBAL NANOMEDICINE MARKET: COMPANY SHARE ANALYSIS, 2021 (%)

FIGURE 14 PFIZER INC.: KEY FINANCIALS

FIGURE 15 JOHNSON & JOHNSON SERVICES, INC., KEY FINANCIALS

FIGURE 16 GENERAL ELECTRIC COMPANY.: KEY FINANCIALS

FIGURE 17 INVITAE CORPORATION.: KEY FINANCIALS

FIGURE 18 LEADIENT BIOSCIENCES INC.: KEY FINANCIALS

FIGURE 19 MERCK & CO., INC.: KEY FINANCIALS

FIGURE 20 DIASORIN S.P.A.: KEY FINANCIALS

FIGURE 21 NANOSPHERE HEALTH SCIENCES, INC.: KEY FINANCIALS

FIGURE 22 CELGENE CORPORATION: KEY FINANCIALS

FIGURE 23 TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY FINANCIALS

Nanomedicine Market Overview:


The global nanomedicine market is expected to cross USD 393,040 million by 2030 at a CAGR of 9.2%. Nanomedicine is one of the nanotechnology applications used to diagnose, treat, monitor, and control biological systems. Nanomedicine is the use of nanoscale material manipulation to improve medicine delivery. Nanomedicine has the potential to enhance early detection, prevention, diagnosis, therapy, and follow-up for a wide range of illnesses, including cancer. According to Alzheimer's Disease International, there will be around 50 million persons with dementia worldwide by 2020. This figure is predicted to double every 20 years, reaching 82 million in 2030 and 152 million in 2050. The increase in R&D activities regarding nanorobots is boosting the demand for the nanomedicine market. The growing burden of chronic and infectious diseases across the globe is driving the market's growth.


COVID-19 Analysis:


The COVID-19 pandemic increased the demand for nanomedicines for the treatment of numerous ailments. Nanomedicine applications opened up new avenues for the creation of innovative solutions for the prevention, diagnosis, and treatment of the COVID-19 virus and other viral illnesses. COVID-19 management was accomplished by the creation of nano-based materials like disinfectants, personal protective equipment, diagnostic systems, and barrier systems for treatment and vaccine development. For instance, in 2020, a research team from the University of Padua's Department of Chemical Sciences researched and proved the efficacy of inorganic 4D nanoparticles in the biomedical area. 4D nanomedicine has various advantages in the biomedical industry, including fewer side effects on live organisms, reduced environmental impact, increased quality of care, and spontaneous effect. This affects the market by increasing the demand for nanomedicines. Overall, the impact of COVID-19 on the nanomedicine market has been reported to be favorable. This was due to a rise in demand for nanomedicines to treat cancer-like disorders. Furthermore, market participants have seen a growth in investments in materials and resources as a result of an increase in nanomedicine R&D activities in all areas.


Furthermore, in other MedTech companies, which were devastated by the COVID-19, the nanomedicine sector was mostly untouched. This is mostly due to the gravity of the health problems for which nanomedicines are used. As a result, persons prescribed nanomedicines before the pandemic continued to take them to retain their quality of life. Despite the fact that the number of new patients receiving nanomedicines slightly decreased during the pandemic's worst months, the need for nanomedicine to detect life-threatening infections early on has fueled the market's continued expansion.


Market Dynamics:


Market Drivers

Increase in R&D activities regarding nanorobots


  • Nanorobots is a rapidly expanding field in nanotechnology. It is anticipated that nanorobots will be introduced in the near future in wide array of applications including defending individuals from sickness, distribution of drugs to heal ailments, and so on. Cancer diagnosis and treatment are expected to be among the potential, but nanorobots will be useful for a wide range of other uses in the future of medicine. The introduction of nanobots for a variety of applications will assist in maximizing market potential and eliminate the need for intrusive operations. As a result, a rise in R&D investment by firms to introduce outstanding nanobots for the healthcare industry is expected to drive worldwide market growth during the forecast period.

  • Furthermore, the high manufacturing and maintenance costs associated with the creation of nanorobots are projected to limit market growth over the projection period. Furthermore, restrictions and technological hurdles imposed during R&D are likely to increase the risk for the company.


Growing burden of chronic and infectious diseases worldwide


  • Chronic diseases are the major cause of death globally. The top causes of mortality globally, accounting for 29 million fatalities, were cardiovascular disease, cancer, chronic respiratory illness, and diabetes. According to the Centers for Disease Control and Prevention (CDC), chronic diseases currently account for 70% of all American fatalities and 75% of the country's annual healthcare costs; nevertheless, chronic illnesses and afflictions are on the increase globally. According to the World Health Organization (WHO), the prevalence of chronic illnesses would have increased by 86% by 2021 Emerging markets will be particularly hard hit, as their populations are predicted to rise the fastest. These factors contribute to the growth of the nanomedicine market.


Market Restraints

Stringent Regulatory Guidelines


  • Regulatory organizations such as the US Environmental Protection Agency and the Food and Drug Administration in the US, as well as the European Commission's Health and Consumer Protection Directorate, have begun to address the possible concerns presented by nanoparticles. So far, neither artificial nanoparticles nor the goods and materials containing them are subjected to any specific production, handling, or labeling regulations. Additionally, the FDA will regulate nanotechnology goods by the unique legal criteria relevant to each type of product within its authority.

  • Furthermore, the most critical ethical issues in nanomedicine are risk assessment, risk management, and risk communication in clinical trials. As a result, the problems of pharmaceutical research and manufacturing apply not just to nanomedicines but also to the products that result from them. On the other hand, their increased knowledge has prompted regulatory authorities to reconsider their current limits. The European Medicines Agency (EMA) may accept follow-on items as a shorter application under the generic or hybrid category in the EU.


Market Opportunities

Rise in out-licensing of nanodrugs and developments in healthcare facilities in the emerging economies 



  • Nanomedicine is regarded as a hot-development field of nanotechnology. The US FDA has approved the commercialization of about 100 nanomedicine applications and devices throughout the last few decades. As a result, growing interest in nanotechnology's potential medicinal applications is producing a new business known as the nanomedicine market. As a result, the US government has provided more than USD 1.4 billion in funding for the national nanotechnology initiative, demonstrating nanotechnology's importance. Furthermore, according to Forbes, nanotechnology is one of the sixth most significant growth technologies to watch over the next decade.


Value Chain Analysis


  • The worldwide nanomedicine market is steadily expanding as nanomedicine products become more popular. Nanomedicine has come a long way in the last few decades nanomedicine includes nanoscale materials such as biocompatible nanoparticles and nanorobots that provide accurate disease diagnosis, monitoring, prevention, control, and therapy. Nanomedicine plays a critical role in developing revolutionary medications with a lower risk of adverse effects and higher efficacy than regular treatments due to unique features like size and form. The industry is in its early stages, with various goods in the works. As a result, the market is likely to increase at a consistent rate during the forecast period. The value chain analysis of the nanomedicine market comprises four major components starting with the R&D and designing, followed by manufacturing the ear health products, distribution & sales, and ends with post-sales services.

  • R&D and designing start with conceptualizing, followed by design, then development, and lastly, testing. The R&D segment comprises 25–30% of the value chain. After the product designs are final, the manufacturing of the product starts. Manufacturing consists of 45–50% of the value chain. The sourcing of raw materials is the initial phase in manufacturing the products. The manufacturing components are sometimes outsourced. Outsourcing eliminates manufacturing process activities of some parts and helps improve the process's efficiency. Then comes distribution and sales, which is essential for any industry. Here, awareness about the products is spread across the market to get interested customers for the product. It consists of 10-15% of the value chain. Lastly, post-sales services account for around 5–10% of the value chain. In this step, customer feedback is taken into consideration to improve upon their existing product portfolio.


Segment Overview

By Product

Nanoparticles



  • The nanoparticles segment is expected to dominate the total nanomedicine market during the forecast period. This is due to the advantages provided by different nanoparticles, as well as the rising use of metal and metal oxide particles in photodynamic therapy (PDT) for cancer and infectious disease treatment, which will increase product demand.


Metal & metal oxide nanoparticles


  • The hydrolysis of metal salts primarily forms metal oxide nanoparticles (MONPs) at temperatures no greater than 100°C. Metal Oxide Nanoparticles are also used to manufacture microelectronic circuits, sensors, piezoelectric devices, fuel cells, coatings for corrosion protection of surfaces, and as catalysts in technical applications.


Liposomes



  • Liposomes are a form of therapeutically proven nanoparticle that has been used commercially to deliver cytotoxic medications, antifungal agents, and vaccinations. Furthermore, liposomes are one of the most well-established nanomedicines in cancer therapy and bioimaging. It contains a lipid bilayer structure that protects and solubilizes both hydrophilic and hydrophobic molecules, comparable to biological cell membranes.


Polymers & polymer-drug conjugates



  • Polymer-drug conjugates are drug molecules encased in polymer molecules that serve as the drug's delivery method. Polymer medicines have passed multidrug resistance (MDR) testing and may one day be used to treat endocrine-related malignancies. The polymer-drug conjugate (PDC) approach has emerged as one of the most promising drug-delivery technologies due to several advantages, such as avoiding premature drug release, providing controlled and targeted drug delivery, and improving conjugated drug stability, safety, and kinetics, and so on.


Hydrogel nanoparticles


  • Hydrogel nanoparticles, also known as polymeric nanogels or macromolecular micelles, are emerging as promising therapeutic drug carriers. These nanostructures are versatile and have features that make them excellent for the transport of bioactive compounds, namely biopharmaceuticals.


Dendrimers


  • Dendrimers are nanoscale, radially symmetric molecules having a well-defined, homogenous, and monodisperse structure consisting of a generally symmetric core, an inner shell, and an outer shell. Moreover, Dendrimers are expected to significantly expand revenue during the projection period due to their unique structure, making them the most effective drug delivery alternative for nanomedicines.


Inorganic nanoparticles



  • Inorganic nanoparticles (INPs) play an essential role in lives due to their use as medicines, imaging agents, and antiseptics. Metal, silica, inorganic dendrimers, organic-inorganic hybrids, and bioinorganic hybrids are among the most promising INPs in development.


Nanoshells



  • Nanoshells are nanoparticles that have a dielectric core and a thin metal covering. There are two types of nanoshells those are carbon nano shells and gold nano shells. This sort of nanoparticle may be employed in dentistry in the near future for a variety of purposes, including the treatment of severe gingival and periodontal infections, the removal of oral and dental cancer cells, and perhaps soft tissue welding of inaccessible areas.


Nanotubes


  • CNTs-based nanomaterials provide a tremendous opportunity to obtain various adjustable properties such as fluorescence, magnetism, optical, affinity, adsorption, and degradability. Furthermore, the rising usage of nanotubes in technological breakthroughs in numerous industries, including medical (Nanomedicines), electronics, engineering, and several other applications, are the primary reasons driving the growth of carbon nanotubes market in the medium term.


Nanodevices



  • Nanodevices are nanoparticles designed to interact with cells and tissues and perform certain tasks. Moreover, nanodevices are projected to significantly influence our abilities to increase energy conversion, reduce pollution, generate food, and improve human health and lifespan.


By Modality

Diagnostics


  • Diagnostic nanoparticles are intended to visualize abnormalities and increase knowledge of key (patho-) physiological principles underlying various diseases and disease therapies. However, because of the high demands on their pharmacokinetic properties and elimination, nano diagnostics are only applicable in a restricted number of scenarios. As a result, the vast majority of nanoparticle compositions used in clinics today are medical. Recent advancements in nanotechnology have created a diverse array of nanoparticle compositions for diagnostic purposes.


Treatments



  • The treatment segment accounted for the largest revenue share in 2021. This is due to the increasing medicinal activity and nanomedicine being used to treat a wide range of life-threatening illnesses, including cancer, diabetes, cardiovascular disease, and others. This is expected to drive treatment sector growth throughout the projection period.


By Application

Drug Delivery



  • The drug delivery segment was the largest contributor to the global market in 2021 and is expected to remain dominant during the forecast period, owing to an increase in the prevalence of diseases such as cancer and the COVID-19 virus, as well as an increase in awareness of the applications of nanomedicines.


Diagnostic Imaging


  • The diagnostic imaging segment, on the other hand, is predicted to develop at the quickest rate in the future years. The field of nanomedicine, or the development of medical technologies employing nanoscale alterations, has grown rapidly in recent years. Targeted drug delivery, controlled drug release, tissue engineering, and in vitro diagnostics have achieved significant advances. These nanoscale advances are reshaping the landscape of modern medicine by enabling benefits such as controlled dispersion, increased sensitivity, and multifunctional materials. Nanotechnologies have also been shown to be extremely beneficial in the vast and critical field of diagnostic imaging.


Vaccines



  • The development of novel and effective vaccines continues to be significant. Numerous researchers have recently demonstrated that nanotechnology-based vaccinations are more efficient than traditional vaccines by using nanotechnology as a beneficial tool for addressing existing vaccine challenges.


Regenerative Medicine



  • Regenerative medicine is a relatively new branch of medicine that tries to restore normal function by replacing, engineering, or regenerating human cells, tissues, and organs lost or damaged due to aging, illness, or congenital faults. The field of regenerative medicine is anticipated to dominate the nanomedicine business by 2030. This is because regenerative medicine has the ability to guide cell destiny, target cell transport, and minimize immune rejection (through encapsulation), all of which contribute to the development of regenerative medications.


Active implants



  • Active implants are among the most technically difficult and dangerous medical devices, requiring extensive applied R&D, design, production, testing, and approval. Drugs have traditionally been administered via active implants such as insulin and morphine pumps. Furthermore, implantable microchips are being investigated for the storage and controlled release of active compounds in order to deliver medications to specified locations at varying rates.


Biomaterials



  • Biomaterials are classified into three types: metals, ceramics, and polymers. Biomaterials and nanoparticles have important roles in nanobiotechnology, notably in diagnostics, drug delivery systems, prostheses, and implants. Nanoscale materials function well with biomedical equipment since most biological systems are nanoscale in size.


Others



  • The other type of application includes wearable devices, antibacterial, and high-throughput screening platforms. Wearable devices are becoming an important aspect of personal analytics, evaluating physical states, collecting physiological information, and guiding medication schedules. These ever-evolving technological platforms not only promise to help individuals live healthier lives but also give continuous medical data for actively tracking metabolic state, diagnosis, and treatment. Nanotechnology has various advantages, including precision pharmaceutical delivery that is target-oriented and site-specific. The use of various types of nanoparticles in the creation of innovative delivery solutions will propel the nanomedicine industry forward.


By Indication

Cardiovascular diseases


  • Cardiovascular diseases are the major cause of disability and death in a large proportion of the world's population. Cardiovascular disorders are a significant reason for nanomedicines' growing popularity. Furthermore, the growing elderly population, as well as an increase in the number of patients suffering from obesity, high blood pressure, and other cardiovascular illnesses, are all contributing to the growth of the nanomedicine market.


Infectious Diseases



  • Nanomedicine can help detect bacterial infections and can deliver antibiotics in a targeted way. Medical devices like catheters and heart valves can be coated in nanomaterials that repel bacteria, which helps prevent infection. According to the World Health Organization, the growing worldwide burden of chronic and infectious diseases is propelling the nanomedicine industry forward.


Orthopedic Diseases



  • Orthopedics includes the spine, bones, joints, ligaments, tendons, muscles, and nerves. Nanomedicine has been used in a variety of innovative orthopedic treatments. Targeted medication delivery, implantable materials, spinal disc regeneration, and diagnostic techniques are a few clinical uses. There is a high demand for bioceramic, despite the fact that their inherent brittleness prevents their use in a wide range of applications. The need for bioceramics has been fueled by increasing advances in biological implants for a variety of surgical operations, including orthopedic and dental treatments.  


Neurological diseases



  • Neurological disorders impact billions of individuals globally, regardless of age, gender, education, or money. Neurological illnesses such as Alzheimer's (AD), Parkinson's (PD), and stroke greatly strain human health. Additionally, the treatment of neurological disorders or tumors is a difficult task that may be readily overcome with nanotechnology if solutions such as multimodal medicines are actively used. Nonetheless, the future holds out hope that the field of nanomedicine will be completely utilized for potentially improved treatment procedures.


Oncological diseases



  • The oncological disease segment is projected to show rapid growth over the forecast period 2022–2030, owing to the increasing global prevalence of cancer. According to GLOBOCAN 2020, the worldwide cancer burden climbed to 19.3 million cases and 10 million cancer deaths in 2020. In comparison to traditional drugs, nanomedicine provides more sensitive cancer diagnosis and better treatment success with significantly fewer adverse effects. The regular release of cancer drugs employing nanomedicine technology significantly boosts the market.


Anti-Inflammatory Disease



  • The worldwide anti-inflammatory disease segment has grown due to factors such as rising autoimmune and respiratory illnesses, new medications in development, and higher anti-inflammatory drug usage.


Others



  • Immunological illnesses, ophthalmological ailments, and urological difficulties are among the various sorts of indications. Nanomedicine has the potential to be applied in genitourinary cancer targeted therapy, erectile dysfunction, hyperactive bladder, bladder reconstruction, the manufacturing of prosthetic kidneys and biodegradable stents, and robotic surgery. Furthermore, some ophthalmology nanomedicine applications are described, such as oxidative stress treatment, intraocular pressure measurement, and the use of nanoparticles to treat choroidal new vessels, prevent scarring after glaucoma surgery, and treat retinal degenerative disease with gene therapy.


By Region

North America:



  • North America's market accounted for the largest share in 2021. This is due high demand for nanomedicines and the availability of advanced healthcare facilities with trained medical professionals.


Asia-Pacific:



  • Asia-Pacific is expected to have the highest CAGR in 2022–2030. This is due to improvements in healthcare infrastructure, a growth in the number of hospitals equipped with instruments, the expansion of the R&D industry, an increase in healthcare reforms, and technological achievements in nanomedicines. Furthermore, the growing number of venture capital investors from developing countries is expected to drive the growth of the region's nanomedicine market in the coming years.


Europe:



  • The European nanomedicine market is being driven by increased government support and funding, growing demand for therapies with fewer side effects, and the cost-effectiveness of therapies. Furthermore, increased nano medication licensing and the growth of healthcare facilities in Europe are projected to give various opportunities for the European nanomedicine sector to thrive. Additionally, the market is increasing as the number of competitors increases, and revolutionary technology is widely used.


Rest of the World:



  • The Middle East and Africa were among the countries in the rest of the world. The increased prevalence of cancer and cardiovascular disease, as well as advancements in nanoscale technology for diagnostic procedures and growing desires for personalized therapeutics. Additionally, the expansion of nanomedicine licensing and healthcare facilities in Middle East & Africa countries is expected to promote the growth of the nanomedicine industry. Furthermore, the use of nanotechnology-based contrast networks, diagnostics, and monitoring of medicinal effects on an unprecedentedly short time scale is likely to drive future growth.


Competitive Landscape


  • The nanomedicine market is profitable, both for existing players as well as new entrants. A substantial level of rivalry is observed among the existing manufacturers in the market. Our analysis revealed that market players had adopted different strategies and innovative R&D techniques to expand their business and secure their position in the global nanomedicine market. For instance, in January 2022, Pfizer and Acuitas Medicines (Canada) collaborated to develop a lipid nanoparticle delivery method for mRNA vaccines and therapeutics. Pfizer will have the opportunity to license Acuitas' LNP technology on a non-exclusive basis for up to ten vaccine or therapeutic targets.

  • Johnson & Johnson Services, Inc. (US) has robust industry experience and is one of the leading companies in the Nanomedicine Market. Furthermore, a high customer satisfaction level, exceptional performance in new markets, and a strong product portfolio add to the company’s competitive advantage. The company also has a strong clientele and is well established in the industry. It is also continuously involved in seminars, conferences, and trade fairs in several countries to generate awareness about its products.

  • Many market players are dominating the global nanomedicine market. The prominent players are involved in strategic agreements, product launches, and joint ventures to sustain their market positions.


List of Key Companies Covered in this report:


  • Pfizer Inc. (US)

  • Johnson & Johnson Services, Inc., (US)

  • General Electric Company (US)

  • Invitae Corporation (US)

  • Leadient BioSciences Inc (Italy)

  • Merck & Co., Inc. (US)

  • DiaSorin S.p.A. (Italy)

  • Nanosphere Health Sciences, Inc. (US)

  • Celgene Corporation (US)

  • Teva Pharmaceutical Industries Ltd. (Israel)


Recent Developments           


  • In January 2022, Pfizer Inc. (US) and Acuitas Medicines (Canada) collaborated to develop a lipid nanoparticle delivery method for mRNA vaccines and therapeutics.

  • In April 2022, Johnson & Johnson (US) launched the Next Satellite Center for global health discovery at the University of Cape Town's Holistic drug discovery and development center, focused on Antimicrobial Resistance (AMR).

  • In February 2022, Invitae (US) launched CE-IVD Cancer Testing Kits in Europe, and the company is anticipated to expand its presence significantly in Europe.

  • In January 2022, Merck KGaA (US) acquired Exelead (US), an Indianapolis-based firm specializing in lipid nanoparticle (LNP)-based drug delivery technology. LNPs are a key part of messenger RNA (mRNA) therapeutics targeting COVID-19 and other diseases.

  • In March 2022, Teva Pharmaceutical Industries Ltd. (Israel) launched its first generic version of Revlimid (lenalidomide capsules) in the US to provide patients with another important treatment option for such extremely challenging conditions.


Report Overview:


  • The study covers the existing short-term and long-term market effects, as well as helps decision-makers to draught short-term and long-term plans for businesses by region. The report covers major regions in North America, Europe, Asia-Pacific, and the Rest of the World. The report analyzes market drivers, restraints, opportunities, challenges, Porter’s Five Forces, Value Chain, and the impact of COVID-19 on the market.


Scope of the Report


  • The scope of the global nanomedicine market study includes a market size analysis and a detailed analysis of the manufacturer’s products and strategies. The market has been segmented based on product, modality, application, indication, and region.


Market Segmentation

Nanomedicine Market by Product


  • Nanoparticles

    • Metal & metal oxide nanoparticles

    • Liposomes

    • Polymers & polymer-drug conjugates

    • Hydrogel nanoparticles

    • Dendrimers

    • Inorganic nanoparticles



  • Nanoshells

  • Nanotubes

  • Nanodevices


Nanomedicine Market, by Modality


  • Diagnostics

  • Treatments


Nanomedicine Market, by Application


  • Drug Delivery

  • Diagnostic Imaging

  • Vaccines

  • Regenerative Medicine

  • Active implants

  • Biomaterials

  • Others


Nanomedicine Market, by Indication


  • Cardiovascular diseases

  • Infectious Diseases

  • Orthopedic diseases

  • Neurological diseases

  • Oncological diseases

  • Anti-Inflammatory Disease

  • Others


Nanomedicine Market, by Region


  • North America

    • US

    • Canada



  • Europe

    • Germany

    • France

    • UK

    • Italy

    • Spain

    • Rest of Europe



  • Asia-Pacific

    • China

    • Japan

    • India

    • Australia

    • South Korea

    • Rest of Asia-Pacific



  • Rest of the World

    • Middle East & Africa

    • Latin America





Report Scope:
Report Attribute/Metric Details
  Market Size   2030: ~USD 393,040 million
  CAGR   9.2%
  Base Year   2021
  Forecast Period   2022–2030
  Historical Data   2018 & 2020
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   By Product, By Modality, By Application, By Indication, and by Region
  Geographies Covered   North America, Europe, Asia-Pacific, Rest of the World
  Key Vendors   Pfizer Inc. (US) Johnson & Johnson Services, Inc., (US) General Electric Company (US) Invitae Corporation (US) Leadient BioSciences Inc (Italy) Merck & Co., Inc. (US) DiaSorin S.p.A. (Italy) Nanosphere Health Sciences, Inc. (US) Celgene Corporation (US) Teva Pharmaceutical Industries Ltd. (Israel)
  Key Market Opportunities   Rise in out-licensing of nanodrugs and developments in healthcare facilities in the emerging economies
  Key Market Drivers   β€’ Increase in R&D activities regarding nanorobots β€’ Growing burden of chronic and infectious diseases worldwide


Speak to Analyst Ask for Customization

Frequently Asked Questions (FAQ) :

The nanomedicine market is growing ata a CAGR of 9.2%. during the forecast period of 2022 to 2030.

The global nanomedicine market is expected to cross USD 393,040 million by 2030.